Glioblastoma multiforme (GBM) is the most common and aggressive type of malignant glioma. Oncolytic adenoviruses are being modified to exploit the aberrant expression of proteins in tumor cells to increase the antiglioma efficacy. E1A mutant adenovirus Delta-24-RGD (DNX-2401) has shown a favorable toxicity profile and remarkable efficacy in a first-in-human phase I clinical trial. However, the comprehensive modulation of glioma metabolism in response to Delta-24-RGD infection is poorly understood. Integrating mass spectrometry based-quantitative proteomics, physical and functional interaction data, and biochemical approaches, we conducted a cell-wide study of cytosolic, nuclear, and secreted glioma proteomes throughout the early time course of Delta-24-RGD infection. In addition to the severe proteostasis impairment detected during the first hours post-infection (hpi), Delta-24-RGD induces a transient inhibition of signal transducer and activator of transcription 3 (STAT3), and transcription factor AP-1 (c-JUN) between 3 and 10hpi, increasing the nuclear factor kappa B (NF-κB) activity at 6hpi. Furthermore, Delta-24-RGD specifically modulates the activation dynamics of protein kinase C (PKC), extracellular signal-regulated kinase 1/2 (ERK1/2), and p38 mitogen-activated protein kinase (p38 MAPK) pathways early in infection. At extracellular level, Delta-24-RGD triggers a time -dependent dynamic production of multitasking cytokines, and chemotactic factors, suggesting potential pleiotropic effects on the immune system reactivation. Taken together, these data help us to understand the mechanisms used by Delta-24-RGD to exploit glioma proteome organization. Further mining of this proteomic resource may enable design and engineering complementary adenoviral based-vectors to increase the specificity and potency against glioma.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6089549PMC
http://dx.doi.org/10.18632/oncotarget.25774DOI Listing

Publication Analysis

Top Keywords

delta-24-rgd infection
12
delta-24-rgd
8
adenovirus delta-24-rgd
8
protein kinase
8
glioma
6
spatial temporal
4
temporal proteome
4
proteome dynamics
4
dynamics glioma
4
glioma cells
4

Similar Publications

Ad5-delta-24-RGD is currently the most clinically advanced recombinant adenovirus (rAd) for glioma therapy. We constructed a panel of fiber-modified rAds (Ad5RGD, Ad5/3, Ad5/35, Ad5/3RGD, and Ad5/35RGD, all harboring the delta-24 modification) and compared their infectivity, replication, reproduction, and cytolytic efficacy in human and rodent glioma cell lines and short-term cultures from primary gliomas. In human cells, both Ad5/35-delta-24 and Ad5/3-delta-24 displayed superior infectivity and cytolytic efficacy over Ad5-delta-24-RGD, while Ad5/3-delta-24-RGD and Ad5/35-delta-24-RGD did not show further improvements in efficacy.

View Article and Find Full Text PDF

Two-cycle cesium chloride (2 × CsCl) gradient ultracentrifugation is a conventional approach for purifying recombinant adenoviruses (rAds) for research purposes (gene therapy, vaccines, and oncolytic vectors). However, rAds containing the RGD-4C peptide in the HI loop of the fiber knob domain tend to aggregate during 2 × CsCl gradient ultracentrifugation resulting in a low infectious titer yield or even purification failure. An iodixanol-based purification method preventing aggregation of the RGD4C-modified rAds has been proposed.

View Article and Find Full Text PDF
Article Synopsis
  • Glioblastoma (GBM) is a tough brain tumor with a suppressive environment, but the new oncolytic virus Delta-24-ACT shows promise as a treatment, especially when paired with immune checkpoint inhibitors (ICIs).
  • Laboratory tests confirmed that Delta-24-ACT effectively infected and killed glioma cells, prolonged survival in mouse models, and modified the tumor environment to promote immune cell activity.
  • Combining Delta-24-ACT with anti-PD-L1 therapy led to significantly better results in tumor-bearing mice than using either treatment alone, suggesting a more effective strategy for attacking GBM.
View Article and Find Full Text PDF
Article Synopsis
  • Oncolytic adenoviruses show promise for treating solid tumors like glioblastoma (GBM), but existing animal models are limited due to species selectivity, necessitating a new approach.
  • Researchers developed an intracranial glioma model using Syrian hamsters that allows for viral replication and immune response assessment, addressing gaps in current models.
  • Findings revealed that the virus Delta-24-RGD effectively kills tumor cells, increases T-cell infiltration in tumors, and significantly improves survival in treated hamsters compared to controls, suggesting the model's potential for future clinical applications.
View Article and Find Full Text PDF
Article Synopsis
  • Delta-24 oncolytic viruses are special adenoviruses designed to target and replicate in cancer cells lacking retinoblastoma 1 (Rb) while sparing normal cells, showcasing advancements in cancer treatment.
  • An adapted version called Delta-24-RGD (DNX-2401) has shown promising results in a phase I trial for recurrent glioblastoma, indicating potential biological and clinical benefits with manageable side effects.
  • The authors review the progress made with Delta-24 therapy, the improvements in its design, and ongoing research efforts to overcome challenges for better effectiveness in treating glioblastoma.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!